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Abstract CRM-197 is a mutated diphtheria toxin (63 000 Da)
widely used as a carrier protein of conjugated vaccines. Among
the 14 histidines of CRM-197, His-21 was found to be modified
selectively with iodoacetamide based reagents. This finding
suggests a simplified method for the preparation of conjugate
vaccines crosslinked to CRM-197. A bifunctional iodoacetamide,
N,NP-(2-hydroxy-1,3-propanediyl)-bis-[2-iodoacetamide] (I-
CH2-CONH-CH2-CH(OH)-CH2-NHCO-CH2-I) (HPBIA),
was synthesized and allowed to react with CRM-197. In the
alkaline buffer of pH 8.0^8.4, HPBIA was shown to react and
intra-bridge His-21 and Lys-24 of CRM-197 sequentially. At
lower pH (7.1^7.5) in the phosphate buffer, the reactivity of Lys-
24 toward HPBIA was suppressed drastically. Under these
conditions, His-21 could be specifically labeled with HPBIA.
Initial experiments have demonstrated that HPBIA modified
CRM-197 is able to crosslink to a cysteine-containing peptide.
These results offer a potential route for improving the
homogeneity of CRM-197 based protein-peptide as well as
protein-polysaccharide conjugates.
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1. Introduction
CRM-197 is a mutated, non-toxic diphtheria toxin [1,2]. A
single GCA mutation which leads to the substitution of Gly-
52 by Glu distinguishes CRM-197 from its wild-type species.
The absence of toxicity of CRM-197 [3,4] is due to the loss of
enzymatic activity of its fragment A, which in the wild type
catalyzes the chemical modi¢cation of elongation factor 2
(translocase) in infected cells that is essential for protein syn-
thesis. This unique non-toxic property, together with its po-
tent immunogenicity, has made CRM-197 a popular carrier
protein for preparation of conjugated vaccines [5^10].
Conjugation with CRM-197 has been typically achieved
through activation of the lysyl residues using various types
of bifunctional crosslinkers. Since CRM-197 contains 40 ly-
sines and many of them are available for crosslinking, the end
products of CRM-197 conjugates are invariably heterogene-
ous. For instance, one of such conjugated vaccines is a novel
anti-idiotype antibody vaccine for melanoma (CGP-62360)
prepared in Novartis [11]. CGP-62360 was produced by cross-
linking CRM-197 via lysine residues to the cysteines of a
partially reduced antibody (IgG2b). Among the 40 total ly-
sines of CRM-197, at least 5 have been shown to be highly
reactive and could be preferentially labeled with a lysine spe-
ci¢c reagent, 4-N,N-dimethylaminoazobenzene-4P-isothiocya-
no-2P-sulfonic acid (S-DABITC) [12]. On the antibody site,
a minimum of two disul¢de bonds become partially reduced
even under mild reducing conditions (1^5 mM of dithiothrei-
tol, 15 min at room temperature) (Knecht and Chang, unpub-
lished data). The multiple crosslinking sites of both CRM-197
and the antibody account for the complexity of the conjugate
formed. CGP-62360 indeed consists of highly heterogeneous
molecular species. This has been characterized by capillary
electrophoresis, mass spectrometry, high resolution electron
microscope, size-exclusion and reversed phase chromatogra-
phy (O’Reilly et al., manuscript in preparation). Even in the
cases of conjugation with small molecular weight moieties, the
multiple activation sites of CRM-197 alone are expected to
generate a high degree of heterogeneity in the end product.
As a consequence of attempts to improve the homogeneity
of the CRM-197 conjugate, we have come across the ¢nding
that histidine residue 21 of the CRM-197 could be selectively
modi¢ed by reagents that possess functional iodoacetamido
groups. In addition, we have also observed that His-21 and
Lys-24 of CRM-197 can be intra-crosslinked and bridged by a
bifunctional iodoacetamide. These properties signal the
unique chemical environment surrounding His-21 and suggest
a potentially useful route of preparing CRM-197 conjugates
with greatly reduced heterogeneity. In this report, we will
describe conditions for the selective modi¢cation of His-21
and the synthesis and application of a crosslinker that was
used to modify His-21 and bridge His-21 and Lys-24 of
CRM-197.
2. Experimental procedures
2.1. Materials
CRM-197 is a mutated wild-type diphtheria toxin. The protein was
supplied by Chiron/Biocine (Siena, Italy) and has a purity of 99.3%
judged by HPLC. A wild-type diphtheria toxin was purchased from
Sigma. The S-DABIA was synthesized and prepared according to the
method described previously in our laboratory [13]. A cysteine con-
taining peptide (Lys-Asn-Gln-Cys-Val-Thr-Gly-Glu) corresponding to
the hirudin sequence residues 36^43 was synthesized by solid phase
method and was kindly supplied by Dr. Hans Rink. TPCK treated
trypsin was purchased from Sigma. All other chemicals used for the
preparation of bu¡ers were obtained from Fluka with a minimum
purity of higher than 99%.
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2.2. Reaction of CRM-197 with S-DABIA
CRM-197 (0.2 mg) was dissolved in 0.2 ml of alkaline bu¡er con-
taining 0.3 mg of S-DABIA. The alkaline bu¡er was either 0.1 M
sodium bicarbonate solution (pH 8.3) or 25 mM sodium phosphate
solution (pH 8.2). Derivatization was carried out at 23‡C in a time
course manner. The samples were then passed through a NAP-5 col-
umn (Pharmacia) and eluted with ammonium bicarbonate bu¡er
(50 mM, pH 7.9). The eluted samples were directly subjected to tryp-
sin digestion.
2.3. Trypsin digestion of S-DABIA labeled CRM-197
S-DABIA derivatized CRM-197 was digested with trypsin in the
ammonium hydrogen carbonate solution (50 mM, pH 7.9) at 23‡C for
24 h. The ¢nal protein concentration was 0.3 mg/ml. The ratio of the
enzyme/substrate by weight was 1:10. After digestion, the sample was
acidi¢ed with 4% tri£uoroacetic acid and was ready for HPLC injec-
tion.
2.4. HPLC analysis of S-DABIA labeled peptides
The chromatographic equipment was a Hewlett Packard 1090
Liquid Chromatograph with diode array detector. The mobile phases
used were: Phase A, 0.1% tri£uoroacetic acid (TFA) purchased from
Pierce, in millipore water. Phase B was 90% gradient grade acetoni-
trile, 10% millipore water and 0.08% TFA. The gradient was 15% B to
60% B in 70 min. The £ow rate was 200 Wl per min. The column was
Vydac C18, 5 Wm, 25 cm, for peptides and proteins. S-DABIA deriv-
atized peptides were detected at 536 nm, isolated from HPLC and
characterized by amino acid sequencing and MALDI mass spectrom-
etry.
2.5. Synthesis of N,NP-(2-hydroxy-1,3-propanediyl)-bis-[2-iodoacet-
amide], I-CH2-CONH-CH2-CH(OH)-CH2-NHCO-CH2-I
(HPBIA)
1,3-Diaminoisopropanol (0.47 g, 5 mM) was dissolved in 15 ml of
acetonitrile/water (1:1, by volume). 4-Nitrophenyliodoacetate (3.08 g,
10 mM) was added in portions by constant stirring. The reaction
temperature was kept below 24‡C using a water bath. After 80 min
of reaction, acetonitrile (10 ml) was added to precipitate the yellowish
mixture. The precipitate was ¢ltered, washed twice with 10 ml of
acetonitrile and ¢nally dried in vacuo for 24 h. The yield was
575 mg (27%). Molecular mass found by MALDI-TOF 426.5 (ex-
pected: 426). Elementary analysis: Found (expected): C: 19.79%
(19.74%); H: 3.12% (2.84%), N: 6.60% (6.58%); I, 59.27% (59.58%).
2.6. Reaction of CRM-197 with HPBIA
CRM-197 (0.2 mg) was dissolved in 0.2 ml of the bu¡er solution
containing 0.2 mg of HPBIA. The bu¡er was either 0.1 M sodium
bicarbonate solution (pH 8.3) or 25 mM sodium phosphate solutions
(pH 8.3, 7.9, 7.5 and 7.1, respectively). Derivatization was carried out
at 23‡C in a time course manner for each bu¡er solution. After the
reaction, the samples were passed through a NAP-5 column (Pharma-
cia), eluted with the sodium bicarbonate bu¡er (50 mM, pH 8.3),
collected in a volume of 550 Wl and immediately introduced with
1 Wl of L-mercaptoethanol in order to block the unreacted iodoacet-
amide of HPBIA. The samples were again passed through a NAP-5
column (Pharmacia), eluted with ammonium bicarbonate bu¡er
(50 mM, pH 7.9) and directly subjected to the trypsin digestion.
2.7. Structural characterization of HPBIA labeled CRM-197
Conditions for trypsin digestion and HPLC analysis of HPBIA
derivatized CRM-197 were similar to those described for the analysis
of S-DABIA labeled samples.
2.8. Crosslinking of HPBIA activated CRM-197 to a cysteine
containing peptide
CRM-197 (0.2 mg) was allowed to react with 0.2 mg of HPBIA in
0.2 ml of sodium phosphate bu¡er (25 mM, pH 7.1). Derivatization
was carried out at 23‡C for 3 h. After the reaction, the samples were
passed through a NAP-5 column (Pharmacia), equilibrated and eluted
with the phosphate bu¡er (50 mM, pH 7.5). HPBIA activated CRM-
197 was collected in a volume of 550 Wl in an Eppendorf tube con-
taining 0.2 mg of the lyophilized octapeptide (Lys-Asn-Gln-Cys-Val-
Thr-Gly-Glu). After 1 h of reaction, the sample was again passed
through a NAP-5 column (Pharmacia), eluted with ammonium bicar-
bonate bu¡er (50 mM, pH 7.9) and directly subjected to sequence
analysis.
2.9. Amino acid sequence analysis and MALDI mass spectrometry
Amino acid sequences of isolated tryptic peptides were determined
by a Hewlett Packard G 1000A sequencer equipped with an on-line
PTH analyzer. All chemicals used to operate the sequencer were also
obtained from Hewlett Packard. An internal standard, 2-nitroaceto-
phenone, which is eluted in between PTH-Ala and PTH-Tyr, was
introduced to ensure precise quantitation of PTH-amino acid. The
MALDI mass spectrometer was a home-built time of £ight (TOF)
instrument with a nitrogen laser of 337 nm wavelength and 3 ns pulse
width. The calibration was performed either externally or internally,
by using standard polypeptides (hypertensin, MW 1031.19; synacthen,
2934.50 and calcitonin, 3418.91).
3. Results
3.1. His-21 of CRM-197 can be selectively modi¢ed with
S-DABIA
The time course of CRM-197 reaction with S-DABITC was
examined. At the desired times, the derivatized samples were
removed from the excess reagent. The extent of S-DABIA
labeling (mole of S-DABIA per mole of CRM-197) can be
estimated from the absorbance of the samples at 465 nm
based on the molar extinction coe⁄cient of S-DABIA
(29 000 at 465 nm and pH 8.0) [13]. Derivatized samples
were subsequently digested with trypsin. Tryptic peptides
were then analyzed by HPLC and monitored simultaneously
at 214 nm and 536 nm in order to detect the S-DABIA labeled
peptides. In both sodium bicarbonate and sodium phosphate
bu¡ers, only one major colored peptide was detected (Fig. 1).
Recovery of this colored peptide reaches a plateau after 2^3 h
of reaction. Sequence analysis and mass analysis unambigu-
ously demonstrate that this peptide corresponds to residues
11^33 of CRM-197, with His-21 labeled with S-DABIA.
It is relevant to mention that the unique reactivity of His-21
is dependent upon the conformation of CRM-197. In the
presence of denaturant (5 M GdmCl), or in case that the
protein is fully reduced and carboxymethylated, the reactivity
of His-21 is no longer detectable with S-DABIA (data not
shown).
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Fig. 1. HPLC tryptic peptides mapping of mutated diphtheria toxin
(CRM-197) derivatized with S-DABIA. S-DABIA derivatization was
performed in the sodium bicarbonate bu¡er (0.1 M, pH 8.3) at
23‡C for 90 min. Additional reaction conditions and HPLC condi-
tions are described in the text. Peptides were monitored at both 214
nm and 536 nm. Only one major color peptide eluted at 29.6 min
was recovered. Structural analysis revealed that this peptide corre-
sponded to residues 11^33 of CRM-197 with His-21 selectively
modi¢ed with S-DABIA.
J.-Y. Chang et al./FEBS Letters 427 (1998) 362^366 363
3.2. Synthesis of iodoacetamide based homo-crosslinkers
The ¢nding that His-21 of CRM-197 can be selectively
modi¢ed by iodoacetamide suggests that as a carrier protein
CRM-197 may be crosslinked to a peptide or protein vaccine
via His-21 alone, thus greatly reducing the heterogeneity of
the CRM-197 conjugate. A homo-crosslinker possessing bi-
functional iodoacetamide was required for this study. We ini-
tially synthesized a N,NP-bis-iodoacetamide with a trimeth-
ylene spacer. This reagent, however, proved to be
unsatisfactory due to its limited solubility in the aqueous sol-
ution at alkaline and neutral pH. Therefore a hydroxyl group
was introduced and a water soluble crosslinker, N,NP-(2-hy-
droxy-1,3-propanediyl)-bis-[2-iodoacetamide] (HPBIA) was
prepared. The structure and purity of HPBIA was con¢rmed
by HPLC, NMR, IR, molecular mass and elementary analy-
sis. The purity of HPBIA is higher than 98%.
3.3. Intra-molecular bridging of His-21 and Lys-24, and
selective modi¢cation of His-21 by HPBIA
Reaction of HPBIA with CRM-197 was ¢rst performed in
the sodium bicarbonate bu¡er (0.1 M, pH 8.3). At di¡erent
time intervals, the reaction was terminated by passing aliquots
of the sample through gel ¢ltration and excess iodoacetamide
was blocked with excess L-mercaptoethanol. The samples were
then digested with trypsin and analyzed by HPLC. Analysis of
time-course trapped samples (Fig. 2) reveals a progressive
decrease of fraction N, a transient intermediate denoted I
that ascends and then descends along the course of reaction
and the subsequent build-up of fraction II. These three frac-
tions were characterized by both amino acid sequencing and
molecular mass analysis. Sequence analysis by Edman chem-
istry con¢rms that fraction N contains a single peptide corre-
sponding to residues 11^33 of CRM-197. His-21 and Lys-24
were recovered quantitatively as derivatives of phenylthiohy-
dantoin at degradation cycles of 11 and 14. Fractions I and II
reveal identical amino acid sequences. However, His is absent
from cycle 11 in the case of fraction I. With fraction II, gaps
were observed at both cycles of 11 and 14. Using MALDI
mass spectrometry, N, I and II display molecular masses of
2622, 2872 and 2793, respectively. These data, taken together,
are consistent with the structures drawn in Fig. 3. N is the
native peptide encompassing residues 11^33 of CRM-197. I
represents the same peptide with single modi¢cation of His-21
by HPBIA and II corresponds to the same peptide with His-
21 and Lys-24 intra-crosslinked by HPBIA. These results thus
vividly demonstrate a sequential modi¢cation and bridging of
His-21 and Lys-24 by HPBIA.
For the purpose of protein conjugation, however, the reac-
tion must end at the single modi¢cation of His-21 and the
formation of fraction I alone. Rationally, this may be
achieved by optimizing the reaction conditions. Therefore, a
systematic study by employing di¡erent bu¡ers of varied pH
was performed. The replacement of sodium bicarbonate bu¡er
by phosphate bu¡er was shown to slow down the modi¢ca-
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Fig. 4. HPLC tryptic peptides mapping of CRM-197 derivatized
with HPBIA in the sodium bicarbonate bu¡er (left column) and so-
dium phosphate bu¡er (right column). HPBIA derivatization was
carried out in a time course manner at 23‡C. The concentration of
bu¡er is 1 M and pH is 8.3. Conditions for enzyme digestion and
HPLC separation are described in the text. Peptides were monitored
at 214 nm. Only the window of the HPLC chromatogram between
26 and 32 min is shown here. Recoveries of three major peptide
fractions (N, I and II) along the course of reaction are indicated.
Fig. 3. Structures HPBIA modi¢ed peptides of CRM-197. (N) is the
native sequence residues 11^33 of CRM-197. (I) is the same peptide
with His-21 selectively modi¢ed with HPBIA (the other end of
HPBIA is coupled to L-mercaptoethanol). (II) represents the same
peptide with His-21 and Lys-24 crosslinked by HPBIA. The struc-
tures were con¢rmed by both amino acid sequencing and mass anal-
ysis.
Fig. 2. HPLC tryptic peptides mapping of CRM-197 derivatized
with HPBIA in a time course manner. HPBIA derivatization was
performed in the sodium bicarbonate bu¡er (0.1 M, pH 8.3) at
23‡C. Conditions for enzyme digestion and HPLC separation are
described in the text. Peptides were monitored at 214 nm. Recovery
of three major peptide fractions, marked N, I and II varies along
the course of reaction. Their structures are shown in Fig. 3.
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tion of Lys-24. At the same pH (8.3) and otherwise identical
reaction conditions (3 h, 23‡C), the application of phosphate
bu¡er reduced the rate of conversion of fraction I to II by a
factor of 2 (Fig. 4). Lowering the pH of phosphate bu¡er has
an even more profound e¡ect of hindering the reaction with
Lys-24. At pH in-between 7.1^7.5, reaction of CRM-197 with
HPBIA occurs almost exclusively at His-21 (Fig. 5).
Conditions (phosphate bu¡er, pH 7.1) that permit selective
modi¢cation of His-21 by HPBIA was applied to prepare
HPBIA activated CRM-197, which was subsequently allowed
to react with a model cysteine-containing peptide (Lys-Asn-
Gln-Cys-Val-Thr-Gly-Glu). After removal of the excess re-
agent, the peptide conjugated CRM-197 was analysed by
mass spectrometry and Edman degradation. The results re-
producibly demonstrated a coupling yield of 25^30% of the
cysteine peptide to the CRM-197.
4. Discussion
The X-ray structure of diphtheria toxin has revealed that
His-21 and Lys-24 are situated within the enzymatic cleft of
the catalytic domain [14]. The region surrounding His-21 and
Lys-24 also bears sequence homology with other toxins that
function as ADP-ribosyltransferase [15,16]. Furthermore, it
has been demonstrated that His-21 of diphtheria toxin can
be selectively modi¢ed with diethyl pyrocarbonate (a histidine
speci¢c reagent) and that this modi¢cation abolishes the en-
zymatic activity of diphtheria toxin [17]. Further study using
mutagenesis has shown that His-21 is important in maintain-
ing the steric conformation required for catalytic activity of
the toxin [18]. CRM-197 is a diphtheria toxin related protein
with only single amino acid substitution. Despite the loss of
toxicity, CRM-197 is believed to adopt a similar 3-D fold as
the wild-type diphtheria toxin. Part of the chemical property
surrounding His-21 of the wild-type species is thus likely to be
preserved in the case of CRM-197 and this should account for
the chemical reactivity of His-21 and Lys-24 observed here.
This proposal is further supported by two relevant observa-
tions: (a) Selective modi¢cation of His-21 of CRM-197 by S-
DABIA occurs only when the protein exists in native form.
When CRM-197 is reduced and carboxymethylated or in the
presence of 5 M GdmCl, the reactivity of His-21 is no longer
detectable. (b) His-21 of both CRM-197 and the wild-type
diphtheria toxin display similar properties toward iodoacet-
amide modi¢cation (data not shown).
Iodoacetamide is known to react speci¢cally with the thiol
group of cysteine [19]. However, iodoacetamide also reacts
with histidine, lysine and methionine residues in special cases,
particularly when those amino acids are located along the
active sites of proteins [20^22]. We have demonstrated in
this report that His-21 of CRM-197 reacts selectively with
S-DABIA, a colored iodoacetamide. Conditions have also
been found that allow His-21 to be preferentially modi¢ed
with one end of HPBIA (a bifunctional iodoacetamide). It is
interesting to notice that while His-21 and Lys-24 could be
sequentially modi¢ed and intra-bridged by HPBIA, only His-
21 is reactive toward mono-functional iodoacetamide, such as
S-DABIA. There are two possible explanations for this result.
One is that modi¢cation of His-21 induces changes of micro-
environment of Lys-24 and renders it inactive toward S-DA-
BIA. Another explanation is that steric hindrance prevents
His-21 and Lys-24 from being modi¢ed simultaneously by
the bulky S-DABIA.
These ¢ndings o¡er a potentially useful route of preparing
CRM-197 based protein-protein conjugate with higher homo-
geneity. We have demonstrated here that CRM-197 is able to
bind to a small cysteine peptide via His-21. It remains to be
shown whether HPBIA activated CRM-197 could e⁄ciently
bind to large proteins with high yield. A high degree of ho-
mogeneity may not be a prime concern for the vaccine e⁄-
cacy. Limitation of the crosslinking site may also reduce the
yield of protein-protein (peptide) conjugation. However, a
homogeneous product will certainly facilitate the task of
structural characterization and quality control that are re-
quired to ensure the consistency of producing CRM-197
based conjugates. In addition, this ¢nding may also provide
a new route to attaching a functional ligand to the catalytic
domain of the diphtheria toxin.
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